The objective of this research proposal is to develop and characterize novel synthetic ligands for thyroid hormone receptors (TRs). TRs belong to the nuclear receptor superfamily of ligand-activated transcription regulators and the physiological effects of thyroid hormone in different tissues are a result of TR-mediated regulation of thyroid hormone responsive genes. There are two genes encoding different TRs, TRalpha and TRbeta, and these two TRs are expressed at different levels in different tissues. We have developed a novel synthetic thyroid hormone analog called GC-1 which is selective for TRbeta. We have characterized the binding and receptor-activation properties of GC-1 and demonstrated that the TRbeta selectivity is high enough to stimulate tissue-selective hormone effects in vivo. The proposed research in this renewal application builds on our success with this family of ligands and is composed of five specific aims.
Aim 1 is focuses on the development of stable cell lines that express either TRalpha or TRbeta and contain a chromosomal copy of a TRE-driven reporter construct. These cell lines will facilitate screening of test ligands in a more efficient and reliable manner than the current assay that relies on transient transfection.
Aims 2 and 3 deal with the development of antagonist ligands for the TR that will block activation of TR responsive genes. For these studies the GC-1 core structure will modified in different ways such that the modification will perturb an important activation surface of the liganded TR complex. These proposed modifications are based on analysis of the crystal structure of TR bound to various ligands including GC-1 and thyroid hormone.
Aim 4 is centered on the development of TRalpha selective ligands. Modifications to the GC-1 core structure are proposed that are designed to form specific H-bonding interactions with TRalpha but not with TRbeta.
In Aim 5 collaborative in vivo experiments are proposed to assess the activity of the synthetic test ligands in a physiologically relevant context. If successful, these studies will provide new selective agonist and antagonist ligands for TRalpha and TRbeta which will be useful as experimental probes of thyroid hormone action in different tissues. Moreover, these selective ligands could be useful as therapeutics for the treatment of human disease associated with thyroid hormone regulation.
| Ferrara, Skylar J; Bourdette, Dennis; Scanlan, Thomas S (2018) Hypothalamic-Pituitary-Thyroid Axis Perturbations in Male Mice by CNS-Penetrating Thyromimetics. Endocrinology 159:2733-2740 |
| Bárez-López, Soledad; Hartley, Meredith D; Grijota-Martínez, Carmen et al. (2018) Sobetirome and its Amide Prodrug Sob-AM2 Exert Thyromimetic Actions in Mct8-Deficient Brain. Thyroid 28:1211-1220 |
| Devereaux, Jordan; Ferrara, Skylar J; Scanlan, Thomas S (2018) Quantification of Thyromimetic Sobetirome Concentration in Biological Tissue Samples. Methods Mol Biol 1801:193-206 |
| Aguayo-Mazzucato, Cristina; Lee Jr, Terence B; Matzko, Michelle et al. (2018) T3 Induces Both Markers of Maturation and Aging in Pancreatic ?-Cells. Diabetes 67:1322-1331 |
| Yu, Guoying; Tzouvelekis, Argyris; Wang, Rong et al. (2018) Thyroid hormone inhibits lung fibrosis in mice by improving epithelial mitochondrial function. Nat Med 24:39-49 |
| Meinig, J Matthew; Ferrara, Skylar J; Banerji, Tania et al. (2017) Targeting Fatty-Acid Amide Hydrolase with Prodrugs for CNS-Selective Therapy. ACS Chem Neurosci 8:2468-2476 |
| Ma, Hongwei; Yang, Fan; Butler, Michael R et al. (2017) Inhibition of thyroid hormone receptor locally in the retina is a therapeutic strategy for retinal degeneration. FASEB J 31:3425-3438 |
| Hartley, Meredith D; Kirkemo, Lisa L; Banerji, Tapasree et al. (2017) A Thyroid Hormone-Based Strategy for Correcting the Biochemical Abnormality in X-Linked Adrenoleukodystrophy. Endocrinology 158:1328-1338 |
| Ferrara, Skylar J; Meinig, J Matthew; Placzek, Andrew T et al. (2017) Ester-to-amide rearrangement of ethanolamine-derived prodrugs of sobetirome with increased blood-brain barrier penetration. Bioorg Med Chem 25:2743-2753 |
| Placzek, Andrew T; Ferrara, Skylar J; Hartley, Meredith D et al. (2016) Sobetirome prodrug esters with enhanced blood-brain barrier permeability. Bioorg Med Chem 24:5842-5854 |
Showing the most recent 10 out of 63 publications
